RISE is a five-year global project funded by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and the U.S. Agency for International Development (USAID). RISE works with countries to achieve a shared vision of attaining and maintaining epidemic control, with stronger local partners capable of managing and achieving results through sustainable, self-reliant and resilient health systems by 2024. RISE’s contributions to this work will lead to fewer new HIV infections, decreased HIV-related morbidity and mortality, and increased quality of life for people living with HIV. With USAID PEPFAR investments, RISE supports countries to achieve and maintain epidemic control by providing strategic technical assistance and direct service delivery to improve HIV prevention, case finding, treatment programming and viral load suppression. The primary objectives of the RISE project are to: 1) attain and maintain HIV epidemic control among at-risk adult men, women and priority populations; 2) attain and maintain HIV epidemic control among key populations; 3) strengthen health systems including improved program management, health information systems, human resources for health and financial systems to ensure attainment and maintenance of epidemic control; and 4) support the transition of direct funding and implementation to capable local partners to meet the PEPFAR goal of 70% of funding to local partners by 2020. The project is led by Jhpiego with the following partners: ICAP at Columbia University, Management Sciences for Health, Anova, BAO Systems, Johns Hopkins University Center for Public Health and Human Rights and Mann Global Health. RISE is currently active in several countries, including Côte d’Ivoire.

This project aims to coordinate and support the government of Côte d’Ivoire in implementing their plans to scale up and institutionalize subcutaneous depot-medroxyprogesterone acetate (DMPA-SC), also known as Sayana^® Press, in their budgeted national family planning strategic plans, in collaboration with the private sector and other national and regional implementing partners. Funded by the Bill & Melinda Gates Foundation, the project seeks to strengthen the country’s capacity for accelerated and autonomous implementation of the DMPA-SC self-injection scale-up plan in collaboration with the government, and coordinated between the public and private sectors, Access Collaborative partners and other implementing partners by end of project.

The human papillomavirus (HPV) vaccine is one of the most effective ways to prevent cervical cancer and other HPV-related diseases, yet there is still disproportionate access to it, specifically among girls and adolescents in low- and middle-income countries. The HAPPI Consortium, funded by the Bill & Melinda Gates Foundation, was launched to increase and sustain equity and program quality, and accelerate coverage of HPV vaccination. John Snow, Inc. and HAPPI Consortium partners Jhpiego, the Clinton Health Access Initiative, International Vaccine Access Center and PATH are focusing on enabling evidence-based policy decisions, enhancing and sustaining equity, improving program quality, providing direct technical assistance in selected countries and monitoring, evaluating and learning to build on the evidence base. Specifically, Jhpiego is supporting the HAPPI/HPV Accelerator-Phase 1 Project to facilitate global coordination and provide HPV vaccine support in several countries, including Côte d’Ivoire.

This grant is a follow-up to the Performance Monitoring for Action project, which used a low-cost, rapid-turnaround survey platform to generate data for decision-making in family planning programs. Under this new grant, the Bill & Melinda Gates Foundation is supporting continued use of the platform for additional data collection and local capacity strengthening.